160 related articles for article (PubMed ID: 38195397)
1. Serum MicroRNA profiles in chronic hepatitis C Egyptian patients before and after combined sofosbuvir and daclatasvir treatment.
Ezzat WM; Amr KS; Tawfeek S; Elbatae H; Bayomi EA; Heiba A; Elhosary Y
BMC Infect Dis; 2024 Jan; 24(1):67. PubMed ID: 38195397
[TBL] [Abstract][Full Text] [Related]
2. Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients.
Hassuna NA; Gamil AN; Mahmoud MS; Mohamed WK; Khairy R
BMC Gastroenterol; 2022 Dec; 22(1):499. PubMed ID: 36463118
[TBL] [Abstract][Full Text] [Related]
3. Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents.
Mashaal AR; Abd El-Hameed M; El Ray AA; Mahmoud Diab T; Dawood RM; Shemis MA; Seyam M
Asian Pac J Cancer Prev; 2022 Sep; 23(9):2965-2971. PubMed ID: 36172658
[TBL] [Abstract][Full Text] [Related]
4. Comparative Real Life Egyptian Experience of the Combination of Sofosbuvir Plus Daclatasvir or Simeprevir for 12 Weeks in Naïve Cirrhotic Patients Infected with HCV Genotype 4.
Ahmed S; Hassan E; Gomaa A; Esamat G; Ramadan A; Ahmed M; Elsayed A; A Wahsh E
Curr Drug Saf; 2023; 18(2):207-213. PubMed ID: 35538812
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Glycated Haemoglobin (HbA1c) Level in Type 2 Diabetic Chronic HCV Non-cirrhotic Treatment-Naïve Egyptian Patients Eradicated with Sofosbuvir Plus Daclatasvir.
Hussein HA; Allam AS; Moaty ASA
Curr Diabetes Rev; 2020; 16(2):165-170. PubMed ID: 31146663
[TBL] [Abstract][Full Text] [Related]
6. Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt.
Nagaty A; Helmy SH; Abd El-Wahab EW
Trans R Soc Trop Med Hyg; 2020 Feb; 114(3):200-212. PubMed ID: 31722032
[TBL] [Abstract][Full Text] [Related]
7. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
[TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03).
Wehmeyer MH; Ingiliz P; Christensen S; Hueppe D; Lutz T; Simon KG; Schewe K; Boesecke C; Baumgarten A; Busch H; Rockstroh J; Schmutz G; Kimhofer T; Berger F; Mauss S; Schulze Zur Wiesch J
J Med Virol; 2018 Feb; 90(2):304-312. PubMed ID: 28710853
[TBL] [Abstract][Full Text] [Related]
9. Serum MicroRNAs as predictors for fibrosis progression and response to direct-acting antivirals treatment in hepatitis C virus genotype-4 Egyptian patients.
Khairy RMM; Hmmad SS; Sayed M; Ahmed HA; Esmail MAM
Int J Clin Pract; 2021 Apr; 75(4):e13954. PubMed ID: 33345414
[TBL] [Abstract][Full Text] [Related]
10. Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience.
Naguib GG; Farid A; Hassan M; Elshafie A; Shazly YE; Shaker MK; Ezzat H; Safwat E; Ahmed OA; Dabbous H; Sherief AF; Hassany M; Elserafy M; Elsayed MH
Arab J Gastroenterol; 2021 Dec; 22(4):285-291. PubMed ID: 34531135
[TBL] [Abstract][Full Text] [Related]
11. Pre-existing, treatment-specific resistance-associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct-acting antivirals.
Sølund C; Pedersen MS; Fahnøe U; Filskov J; Jenssen H; Weis N; Schønning K; Bukh J
APMIS; 2023 Aug; 131(8):426-433. PubMed ID: 37355962
[TBL] [Abstract][Full Text] [Related]
12. Expression profiling of miRNA-196a biomarker in naïve hepatitis C virus-infected and Sofosbuvir plus Daclatasvir-treated patients.
Hussain N; Farooq N; Maqsood M; Rajoka MSR; Bilal M
Arch Microbiol; 2021 Jul; 203(5):2365-2371. PubMed ID: 33660021
[TBL] [Abstract][Full Text] [Related]
13. Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.
Abdelaty LN; Elnaggar AA; Said AA; Hussein RRS
Curr Drug Saf; 2020; 15(1):53-60. PubMed ID: 31573893
[TBL] [Abstract][Full Text] [Related]
14. Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.
Shiha G; Soliman R; ElBasiony M; Hassan AA; Mikhail NNH
Hepatol Int; 2018 Jul; 12(4):339-347. PubMed ID: 29663115
[TBL] [Abstract][Full Text] [Related]
15. Polymorphism in interferon λ3/interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy.
Khan AJ; Saraswat VA; Ranjan P; Parmar D; Negi TS; Mohindra S
J Med Virol; 2019 Apr; 91(4):659-667. PubMed ID: 30431653
[TBL] [Abstract][Full Text] [Related]
16. Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients.
Mohamed MS; Hanafy AS; Bassiony MAA; Hussein S
Eur J Gastroenterol Hepatol; 2017 Dec; 29(12):1368-1372. PubMed ID: 28953002
[TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
Goel A; Bhargava R; Rai P; Aggarwal R
Indian J Gastroenterol; 2017 May; 36(3):227-234. PubMed ID: 28656492
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir, Pegylated Interferon and Ribavirin in the Treatment of an Egyptian Cohort with Hepatitis C Virus Infection in Real-Life Clinical Practice.
Abd-Elsalam S; Badawi R; Elnawasany S; Yousef M; Mansour L; Hawash N; Elkhouly RA; Soliman S; Selim A; Kobtan A; Elfert A
Infect Disord Drug Targets; 2019; 19(2):179-184. PubMed ID: 30207250
[TBL] [Abstract][Full Text] [Related]
19. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
Akhil MS; Kirushnan B; Martin M; Arumugam K; Ganesh Prasad NK; Ravichandran R
Nephrology (Carlton); 2018 May; 23(5):446-452. PubMed ID: 28339162
[TBL] [Abstract][Full Text] [Related]
20. Relation between microRNA-21, transforming growth factor β and response to treatment among chronic hepatitis C patients.
Ghazy AA; Osman EM; Rashwan EA; Gaballah AH; Mostafa H; Tawfik S
J Med Virol; 2019 Dec; 91(12):2166-2173. PubMed ID: 31368531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]